pharmachologic effect
Semisynthetic antibiotic group of macrolides. Suppresses the synthesis of proteins in a microbial cell, interacting with the 50S ribosomal subunit of bacteria. Acts mainly bacteriostatically, as well as bactericidal.

It is active against Gram-positive bacteria: Streptococcus spp., Staphylococcus spp., Listeria monocytogenes, Corynebacterium spp .; Gram-negative bacteria: Helicobacter pylori, Haemophilus influenzae, Haemophilus ducreyi, Moraxella catarrhalis, Bordetella pertussis, Neisseria gonorrhoeae, Neisseria meningitidis, Borrelia burgdorferi; anaerobic bacteria: Eubacterium spp., Peptococcus spp., Propionibacterium spp., Clostridium perfringens, Bacteroides melaninogenicus; intracellular microorganisms: Legionella pneumophila, Chlamydia trachomatis, Chlamydophila pneumoniae, Ureaplasma urealyticum, Mycoplasma pneumoniae.

It is also active against Toxoplasma gondii, Mycobacterium spp. (except Mycobacterium tuberculosis).

Indications
Treatment of infectious and inflammatory diseases caused by pathogens sensitive to clarithromycin: infections of the upper respiratory tract and ENT organs (tonsillopharyngitis, otitis media, acute sinusitis); infection of the lower respiratory tract (acute bronchitis, exacerbation of chronic bronchitis, community-acquired bacterial and atypical pneumonia); odontogenic infections; infections of the skin and soft tissues; mycobacterial infections (M.avium complex, M. kansasii, M.marinum, M. leprae) and their prophylaxis in AIDS patients; eradication of Helicobacter pylori in patients with duodenal ulcer or stomach ulcer (only in combination therapy).